Hyperopia Epidemiology Forecast 2026-2035

Hyperopia, or farsightedness, is a common refractive error affecting global vision health. According to Eye Health Central, up to 30.6% of adults worldwide may be affected by hyperopia, with notable regional variations. According to the hyperopia epidemiology forecast, the global burden is expected to remain significant, driven by demographic changes and increasing awareness of eye care.

Hyperopia Epidemiology Forecast Report Coverage

The analyst's “Hyperopia Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of hyperopia. It projects the future incidence and prevalence rates of hyperopia cases across various populations. The study covers age, gender, and type as major determinants of the hyperopia population. The report highlights patterns in the prevalence of hyperopia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of hyperopia in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Hyperopia Understanding: Disease Overview

Hyperopia, commonly known as farsightedness, is a refractive error in which distant objects are seen more clearly than near objects. It occurs when the eyeball is shorter than normal, or the cornea has insufficient curvature, causing light rays to focus behind the retina instead of directly on it. This condition can lead to blurred near vision, eye strain, and headaches. Hyperopia may be classified as low, moderate, and high degrees based on severity. It can be present from birth and may become more noticeable with age as the eye’s ability to focus declines.

Hyperopia Epidemiology Perspective

The hyperopia epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the hyperopia epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hyperopia and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the American Academy of Ophthalmology, hyperopia is common in early life, with most full-term infants mildly affected. Prevalence declines from 4-9% at 6-9 months to 3.6% at 12 months, reflecting normal visual development and emmetropization processes.
• As per Eye Health Central, global prevalence varies widely by age and region, with about 8.4% of children affected at age six, declining to 1% by age fifteen, while adult prevalence rises from 9.9% in younger adults to 14.9% in older populations.
• According to the Multi-Ethnic Pediatric Eye Disease Study, prevalence differs across ethnic groups, affecting 26.9% of Hispanics, 25% of non-Hispanic White Americans, 20.8% of African Americans, and 13% of Asian Americans, indicating significant demographic variability in hyperopia distribution.
• As per available data, hyperopia shows no strong gender-specific dominance but increases with advancing age, particularly between 45 and 65 years, where it is more common than myopia, highlighting age-related refractive changes and lens elasticity decline.
• According to the American Academy of Ophthalmology, hyperopia has negligible mortality but significant morbidity, with uncorrected moderate-to-high hyperopia (greater than +3.50 diopters) increasing the risk of strabismus up to 13-fold by age four, emphasizing early detection and correction importance.

Country-wise Hyperopia Epidemiology

The hyperopia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the regions, hyperopia shows clear regional and demographic variation in prevalence. In the United States, prevalence is approximately 10% (around 14 million people), with overall rates of 20-30% and 35-40% among adults over forty, as per the American Academy of Ophthalmology and Eye Health Central. In Europe, prevalence is estimated at 23.1% of the population, according to Eye Health Central. In Japan, hyperopia prevalence reaches around 20% in older adults, whereas India reports a lower overall prevalence (approximately 12-18% regionally in Asia) due to a higher myopia burden, as per Eye Health Central, highlighting distinct regional epidemiological patterns.

Hyperopia: Treatment Overview

The treatment of hyperopia focuses on correcting the refractive error to improve visual clarity and reduce associated symptoms. The most common methods include prescription eyeglasses with convex lenses and contact lenses, both of which help redirect light onto the retina. Refractive surgical procedures such as LASIK (Laser-Assisted In Situ Keratomileusis) and PRK (Photorefractive Keratectomy) can permanently reshape the cornea to correct vision. In some cases, especially for severe hyperopia, lens replacement surgery may be considered. Regular eye examinations are essential to monitor progression and adjust corrective measures as needed.

Key Questions Answered

• What are the key findings of hyperopia epidemiology in the 8 major markets?
• What will be the total number of patients with hyperopia across the 8 major markets during the forecast period?
• What was the country-wise hyperopia epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of hyperopia patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hyperopia during the forecast period of 2026-2035?
• What are the currently available treatments for hyperopia?
• What are the disease risks, signs, symptoms, and unmet needs of hyperopia?

Scope of the Hyperopia Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hyperopia based on several factors.
• Hyperopia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hyperopia report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.